{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,15]],"date-time":"2026-04-15T23:00:05Z","timestamp":1776294005263,"version":"3.50.1"},"reference-count":29,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,11,19]],"date-time":"2025-11-19T00:00:00Z","timestamp":1763510400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100032128","name":"Taiho Oncology","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100032128","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["P30 CA008748"],"award-info":[{"award-number":["P30 CA008748"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","esmoopen.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["ESMO Open"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1016\/j.esmoop.2025.105932","type":"journal-article","created":{"date-parts":[[2025,12,30]],"date-time":"2025-12-30T17:04:37Z","timestamp":1767114277000},"page":"105932","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["A phase II study of the AKT inhibitor TAS-117 in patients with advanced solid tumors and germline PTEN mutations"],"prefix":"10.1016","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6467-3632","authenticated-orcid":false,"given":"J.","family":"R\u00f3don","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H.-T.","family":"Arkenau","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7568-8626","authenticated-orcid":false,"given":"P.","family":"Funchain","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Hervieu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"K.","family":"Anthony","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.P.","family":"Chawla","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T.W.","family":"Laetsch","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9027-2891","authenticated-orcid":false,"given":"Y.R.","family":"Murciano-Goroff","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1294-0027","authenticated-orcid":false,"given":"C.F.","family":"Singer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Y.","family":"He","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Mina","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3962-5932","authenticated-orcid":false,"given":"V.","family":"Wacheck","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2106-9165","authenticated-orcid":false,"given":"S.","family":"Delaloge","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.esmoop.2025.105932_bib1","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1038\/s41568-019-0216-7","article-title":"The PI3K-AKT network at the interface of oncogenic signalling and cancer metabolism","volume":"20","author":"Hoxhaj","year":"2020","journal-title":"Nat Rev Cancer"},{"issue":"1","key":"10.1016\/j.esmoop.2025.105932_bib2","doi-asserted-by":"crossref","first-page":"1618","DOI":"10.1038\/s41467-022-29227-2","article-title":"Comprehensive characterization of PTEN mutational profile in a series of 34,129 colorectal cancers","volume":"13","author":"Serebriiskii","year":"2022","journal-title":"Nat Commun"},{"issue":"2","key":"10.1016\/j.esmoop.2025.105932_bib3","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1158\/1078-0432.CCR-11-2283","article-title":"Lifetime cancer risks in individuals with germline PTEN mutations","volume":"18","author":"Tan","year":"2012","journal-title":"Clin Cancer Res"},{"issue":"2","key":"10.1016\/j.esmoop.2025.105932_bib4","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1172\/JCI121277","article-title":"PTEN-opathies: from biological insights to evidence-based precision medicine","volume":"129","author":"Yehia","year":"2019","journal-title":"J Clin Invest"},{"issue":"8","key":"10.1016\/j.esmoop.2025.105932_bib5","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1016\/j.ctrv.2010.04.002","article-title":"Cowden syndrome","volume":"36","author":"Farooq","year":"2010","journal-title":"Cancer Treat Rev"},{"issue":"3","key":"10.1016\/j.esmoop.2025.105932_bib6","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1038\/sj.ejhg.5200289","article-title":"Novel PTEN mutations in patients with Cowden disease: absence of clear genotype-phenotype correlations","volume":"7","author":"Nelen","year":"1999","journal-title":"Eur J Hum Genet"},{"key":"10.1016\/j.esmoop.2025.105932_bib7","series-title":"StatPearls. Treasure Island, FL","article-title":"Cowden disease","author":"Garofola","year":"2023"},{"issue":"5","key":"10.1016\/j.esmoop.2025.105932_bib8","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1016\/S0190-9622(83)70081-2","article-title":"Cowden\u2019s disease (multiple hamartoma and neoplasia syndrome). A case report and review of the English literature","volume":"8","author":"Salem","year":"1983","journal-title":"J Am Acad Dermatol"},{"issue":"10","key":"10.1016\/j.esmoop.2025.105932_bib9","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1097\/GIM.0b013e3181ac9aea","article-title":"PTEN hamartoma tumor syndrome: an overview","volume":"11","author":"Hobert","year":"2009","journal-title":"Genet Med"},{"issue":"15","key":"10.1016\/j.esmoop.2025.105932_bib10","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1056\/NEJMoa1912735","article-title":"Selumetinib in children with inoperable plexiform neurofibromas","volume":"382","author":"Gross","year":"2020","journal-title":"N Engl J Med"},{"issue":"26","key":"10.1016\/j.esmoop.2025.105932_bib11","doi-asserted-by":"crossref","first-page":"2509","DOI":"10.1056\/NEJMoa1500596","article-title":"PD-1 blockade in tumors with mismatch-repair deficiency","volume":"372","author":"Le","year":"2015","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.esmoop.2025.105932_bib12","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1056\/NEJMoa1706450","article-title":"Olaparib for metastatic breast cancer in patients with a germline BRCA mutation","volume":"377","author":"Robson","year":"2017","journal-title":"N Engl J Med"},{"issue":"34","key":"10.1016\/j.esmoop.2025.105932_bib13","doi-asserted-by":"crossref","first-page":"4103","DOI":"10.1200\/JCO.24.00427","article-title":"US Food and Drug Administration approval summary: capivasertib with fulvestrant for hormone receptor-positive, human epidermal growth factor receptor 2-negative locally advanced or metastatic breast cancer with PIK3CA\/AKT1\/PTEN alterations","volume":"42","author":"Dilawari","year":"2024","journal-title":"J Clin Oncol"},{"issue":"7","key":"10.1016\/j.esmoop.2025.105932_bib14","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1016\/j.annonc.2024.04.005","article-title":"Recommendations for the use of next-generation sequencing (NGS) for patients with advanced cancer in 2024: a report from the ESMO Precision Medicine Working Group","volume":"35","author":"Mosele","year":"2024","journal-title":"Ann Oncol"},{"issue":"suppl 1","key":"10.1016\/j.esmoop.2025.105932_bib15","doi-asserted-by":"crossref","first-page":"S2","DOI":"10.1038\/sj.bjc.6601629","article-title":"Fulvestrant: an oestrogen receptor antagonist with a novel mechanism of action","volume":"90","author":"Osborne","year":"2004","journal-title":"Br J Cancer"},{"key":"10.1016\/j.esmoop.2025.105932_bib16","article-title":"Exceptional response to AKT inhibition in patients with breast cancer and germline PTEN mutations","volume":"3","author":"Kingston","year":"2019","journal-title":"JCO Precis Oncol"},{"issue":"4","key":"10.1016\/j.esmoop.2025.105932_bib17","doi-asserted-by":"crossref","first-page":"435","DOI":"10.3390\/cancers11040435","article-title":"PTEN as a prognostic\/predictive biomarker in cancer: an unfulfilled promise?","volume":"11","author":"Bazzichetto","year":"2019","journal-title":"Cancers (Basel)"},{"issue":"2","key":"10.1016\/j.esmoop.2025.105932_bib18","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1016\/j.jid.2018.07.031","article-title":"Revisiting the clinical and biologic relevance of partial PTEN loss in melanoma","volume":"139","author":"Giles","year":"2019","journal-title":"J Invest Dermatol"},{"issue":"1","key":"10.1016\/j.esmoop.2025.105932_bib19","doi-asserted-by":"crossref","first-page":"161","DOI":"10.3892\/ol.2013.1331","article-title":"PTEN mutation, methylation and expression in breast cancer patients","volume":"6","author":"Zhang","year":"2013","journal-title":"Oncol Lett"},{"issue":"suppl 6","key":"10.1016\/j.esmoop.2025.105932_bib20","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/S0959-8049(12)72154-8","article-title":"356 Characterization of TAS-117, a novel, highly potent and selective inhibitor of AKT","volume":"48","author":"Abe","year":"2012","journal-title":"Eur J Cancer"},{"issue":"6","key":"10.1016\/j.esmoop.2025.105932_bib21","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1007\/s00280-023-04631-7","article-title":"A first-in-human phase I study of TAS-117, an allosteric AKT inhibitor, in patients with advanced solid tumors","volume":"93","author":"Doi","year":"2024","journal-title":"Cancer Chemother Pharmacol"},{"issue":"5","key":"10.1016\/j.esmoop.2025.105932_bib22","doi-asserted-by":"crossref","first-page":"1366","DOI":"10.1007\/s10637-021-01085-7","article-title":"Phase 2 study of TAS-117, an allosteric akt inhibitor in advanced solid tumors harboring phosphatidylinositol 3-kinase\/v-akt murine thymoma viral oncogene homolog gene mutations","volume":"39","author":"Lee","year":"2021","journal-title":"Invest New Drugs"},{"issue":"30","key":"10.1016\/j.esmoop.2025.105932_bib23","doi-asserted-by":"crossref","first-page":"3377","DOI":"10.2217\/fon-2022-0305","article-title":"A phase II study of TAS-117 in patients with advanced solid tumors harboring germline PTEN-inactivating mutations","volume":"18","author":"Rod\u00f3n","year":"2022","journal-title":"Future Oncol"},{"issue":"20","key":"10.1016\/j.esmoop.2025.105932_bib24","doi-asserted-by":"crossref","first-page":"2191","DOI":"10.1001\/jama.2013.281053","article-title":"World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects","volume":"310","year":"2013","journal-title":"JAMA"},{"key":"10.1016\/j.esmoop.2025.105932_bib25","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2021.662232","article-title":"AKT inhibitors: new weapons in the fight against breast cancer?","volume":"12","author":"Martorana","year":"2021","journal-title":"Front Pharmacol"},{"issue":"suppl 10","key":"10.1016\/j.esmoop.2025.105932_bib26","doi-asserted-by":"crossref","first-page":"x21","DOI":"10.1093\/annonc\/mdz440","article-title":"Management of toxicity to isoform \u03b1-specific PI3K inhibitors","volume":"30","author":"Nunnery","year":"2019","journal-title":"Ann Oncol"},{"issue":"8","key":"10.1016\/j.esmoop.2025.105932_bib27","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1200\/JCO.2011.36.1196","article-title":"PI3K\/AKT\/mTOR inhibitors in patients with breast and gynecologic malignancies harboring PIK3CA mutations","volume":"30","author":"Janku","year":"2012","journal-title":"J Clin Oncol"},{"issue":"6","key":"10.1016\/j.esmoop.2025.105932_bib28","doi-asserted-by":"crossref","DOI":"10.1101\/mcs.a006134","article-title":"Case report: five-year experience of AKT inhibition with miransertib (MK-7075) in an individual with Proteus syndrome","volume":"7","author":"Ours","year":"2021","journal-title":"Cold Spring Harb Mol Case Stud"},{"issue":"13","key":"10.1016\/j.esmoop.2025.105932_bib29","doi-asserted-by":"crossref","first-page":"3120","DOI":"10.3390\/cancers13133120","article-title":"PTEN hamartoma tumor syndrome\/Cowden syndrome: genomics, oncogenesis, and imaging review for associated lesions and malignancy","volume":"13","author":"Dragoo","year":"2021","journal-title":"Cancers (Basel)"}],"container-title":["ESMO Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2059702925018022?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2059702925018022?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T17:51:51Z","timestamp":1773942711000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2059702925018022"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":29,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["S2059702925018022"],"URL":"https:\/\/doi.org\/10.1016\/j.esmoop.2025.105932","relation":{},"ISSN":["2059-7029"],"issn-type":[{"value":"2059-7029","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A phase II study of the AKT inhibitor TAS-117 in patients with advanced solid tumors and germline PTEN mutations","name":"articletitle","label":"Article Title"},{"value":"ESMO Open","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.esmoop.2025.105932","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Ltd on behalf of European Society for Medical Oncology.","name":"copyright","label":"Copyright"}],"article-number":"105932"}}